Celldex Therapeutics, Inc.

CLDX · Nasdaq · SIC 2835: In Vitro & In Vivo Diagnostic Substances
334
SEC Filings

Business Summary

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on mast cell biology, developing therapeutic monoclonal and bispecific antibodies for severe inflammatory, allergic, and autoimmune diseases. Its lead candidate, Barzolvolimab (CDX-0159), a KIT receptor inhibitor, is in Phase 3 trials for Chronic Spontaneous Urticaria and Phase 2 trials for Prurigo Nodularis and Atopic Dermatitis. Its bispecific pipeline includes CDX-622, targeting TSLP and SCF for inflammatory diseases.

Next Earnings

Q2 FY2026 — expected 2026-08-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCLDXdiscussed_in_filing Cybersecurity
topic_mentionCLDXdiscussed_in_filing Trusted Computing
topic_mentionCLDXdiscussed_in_filing Blockchain & Crypto
topic_mentionCLDXdiscussed_in_filing Regulation
topic_mentionCLDXdiscussed_in_filing Healthcare & Bio
topic_mentionCLDXdiscussed_in_filing Platform & Ecosystem
topic_mentionCLDXdiscussed_in_filing Cybersecurity
topic_mentionCLDXdiscussed_in_filing Trusted Computing
topic_mentionCLDXdiscussed_in_filing Blockchain & Crypto
topic_mentionCLDXdiscussed_in_filing Regulation
topic_mentionCLDXdiscussed_in_filing Healthcare & Bio
topic_mentionCLDXdiscussed_in_filing Platform & Ecosystem
topic_mentionCLDXdiscussed_in_filing Cybersecurity
topic_mentionCLDXdiscussed_in_filing Trusted Computing
topic_mentionCLDXdiscussed_in_filing Blockchain & Crypto
topic_mentionCLDXdiscussed_in_filing Regulation
topic_mentionCLDXdiscussed_in_filing Healthcare & Bio
topic_mentionCLDXdiscussed_in_filing Platform & Ecosystem
topic_mentionCLDXdiscussed_in_filing Cybersecurity
topic_mentionCLDXdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-252025-12-310001104659-26-019652EDGAR78K words
2025-02-272024-12-310001410578-25-000216EDGAR—
2024-02-262023-12-310001410578-24-000076EDGAR—
2023-02-282022-12-310001104659-23-026701EDGAR—
2022-02-282021-12-310001104659-22-028070EDGAR—
2021-03-292020-12-310001104659-21-043161EDGAR—
2020-03-262019-12-310001047469-20-001809EDGAR—
2019-03-072018-12-310001047469-19-000992EDGAR—
2018-03-072017-12-310001047469-18-001363EDGAR—
2017-03-142016-12-310001047469-17-001564EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001104659-25-109137EDGAR24K words
2025-08-072025-06-300001410578-25-001610EDGAR—
2025-05-082025-03-310001410578-25-001111EDGAR—
2024-11-062024-09-300001410578-24-001766EDGAR—
2024-08-082024-06-300001410578-24-001219EDGAR—
2024-05-062024-03-310001410578-24-000593EDGAR—
2023-11-022023-09-300001410578-23-002169EDGAR—
2023-08-082023-06-300001410578-23-001588EDGAR—
2023-05-042023-03-310001104659-23-055992EDGAR—
2022-11-092022-09-300001104659-22-116466EDGAR—
2022-08-082022-06-300001104659-22-087222EDGAR—
2022-05-052022-03-310001104659-22-056442EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001104659-26-038882EDGAR25K words
2026-02-250001171843-26-001098EDGAR—
2025-11-100001171843-25-007179EDGAR—
2025-08-190001104659-25-080248EDGAR—
2025-08-070001171843-25-005181EDGAR—
2025-06-060001104659-25-057066EDGAR—
2025-05-080001171843-25-002980EDGAR—
2025-02-270001171843-25-001126EDGAR—
2024-11-060001171843-24-006056EDGAR—
2024-08-080001171843-24-004603EDGAR—

334 total filings indexed. 302 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ACHV — ACHIEVE LIFE SCIENCES, INC. TKNO — Alpha Teknova, Inc. AWHL — Aspira Women's Health Inc. BMRA — BIOMERICA INC BZYR — BURZYNSKI RESEARCH INSTITUTE INC CDIO — Cardio Diagnostics Holdings, Inc. IDXX — IDEXX LABORATORIES INC /DE ICCC — IMMUCELL CORP /DE/

Tags

chronic-spontaneous-urticaria chronic-inducible-urticaria prurigo-nodularis atopic-dermatitis inflammatory-and-autoimmune-diseases allergic-diseases

Company Identity

CIK0000744218
TickerCLDX
ExchangeNasdaq
SIC2835: In Vitro & In Vivo Diagnostic Substances
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 214284389942a555ec1f4b595b50d6b07797437ba76328bed0df06a729f481a8
parent: 1afee3267253bb4696eb13a1f191176fa7e9e6505cfddd24262fb4ac7fb6105d
content hash: bd57d88c9592418b05aa4692c3c516f6e41c0bb26da8b1ab0531d489658a1b3b
signed: 2026-04-13T04:44:21.244Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf